Kenvue Drives Climate Action Strategy Forward
23.9.2024 12:45:00 CEST | Business Wire | Press Release
Kenvue Inc. (NYSE: KVUE) (“Kenvue” or the “Company”), the maker of iconic brands such as Aveeno®, Listerine®, Neutrogena® and Tylenol®, is advancing progress toward the climate change goals outlined in its Healthy Lives Mission environmental, social and governance strategy, including releasing its first Task Force on Climate-related Financial Disclosures (TCFD) report.
“Publishing our TCFD report represents an important step in our proactive approach to integrating climate considerations into our business strategy, operations, value chain and marketed products,” said Pamela Gill-Alabaster, Global Head of ESG & Sustainability at Kenvue. “We have made meaningful progress, including the validation of our near-term greenhouse gas (GHG) emissions reduction targets by the Science Based Targets initiative (SBTi) and the release of our inaugural Healthy Lives Mission report in support of our ambition to help contribute to a healthier future.”
Healthy Lives Mission was developed with the understanding that human health is inseparably linked to environmental health. Consumers also see this connection, with three out of four adults globally seeing a link between human health and climate change according to an online survey commissioned by Kenvue earlier this year5. The same survey revealed that 86% of people expect health-related consequences of climate change to worsen over the next 5 to 10 years.
Kenvue’s climate change goals and commitments are part of the Healthy Planet pillar of its Healthy Lives Mission strategy and focus on advancing sustainability across the Company’s operations — from product and packaging design to material sourcing, manufacturing and transportation. Highlights on progress as reported in the Healthy Lives Mission 2023 Report include:
- Investments in energy efficiency and decarbonization projects have resulted in Scope 1 and 2 GHG1, 2, 3 reductions of 26% since 2020.
- 21% of the Company’s suppliers, by emissions covering purchased goods and services and upstream transportation and distribution, have science-based targets.
- Use of renewable electricity4 has increased to 65% of its electricity usage through 18 onsite solar-powered electricity systems, offsite renewable electricity4 procurement contracts and the addition of onsite solar installations.
- Using circular economy design principles, Kenvue increased its use of recyclable6 or refillable7 packaging8 to 71% of its portfolio and reduced the volume of virgin plastic9 in packaging8 by 21%.
Since the beginning of 2024, Kenvue has completed new onsite solar installations at its Sezanne, France, and Madra, Greece manufacturing sites, which will provide 1.75MW and 0.186MW of renewable energy, respectively. The Company also expects to complete additional onsite solar installations at its Cape Town, South Africa, Minhang, China and Jakarta, Indonesia manufacturing sites this year, further advancing progress toward its goal of 100% of its electricity usage for its operations1 being renewable4 by 203010, 11.
To address Scope 3 indirect upstream GHG emissions, Kenvue launched a Supplier Climate Action Program in July to engage purchased goods and services and upstream transportation and distribution suppliers. Through this program, the Company will help these suppliers set science-based targets of their own and work to decarbonize their operations. Kenvue has also joined the Energize program, which is designed to help suppliers learn about renewable electricity and provide sourcing opportunities, either as sole sourced or with other suppliers.
Recognizing the value of collaboration to accelerate progress within and across sectors, Kenvue is an active member of several coalitions that have focused workstreams which support climate action and the journey toward net zero including the WWF Climate Business Network and the WWF Renewable Thermal Collaborative. Most recently, Kenvue joined the Forum for the Future’s Climate and Health Coalition to support the integrated transformation of human health and climate systems toward outcomes that deliver benefits for both people and planet.
To read the Kenvue Healthy Lives Mission 2023 Report, visit www.kenvue.com/hlm-report-2023. To access the full TCFD report, visit https://www.kenvue.com/task-force-on-climate-related-financial-disclosures-2023-report.
About Kenvue
Kenvue is the world’s largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson’s®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we believe in the extraordinary power of everyday care and our teams work every day to put that power in consumers’ hands and earn a place in their hearts and homes. Learn more at www.kenvue.com.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995, including forward-looking statements related to, among other things, risks and opportunities associated with the Healthy Lives Mission, climate, forests and our related ESG estimates, projections, goals, targets, commitments and expected results. Forward-looking statements may be identified by the use of words such as “plans,” “expects,” “may,” “will,” “anticipates,” “estimates,” “intends,” “goal,” “target,” “commitment,” and other words of similar meaning. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kenvue and its affiliates.
A list and descriptions of risks, uncertainties, and other factors can be found in Kenvue’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and subsequent Quarterly Reports on Form 10-Q and other filings, available at www.kenvue.com or on request from Kenvue. Kenvue and its affiliates undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or developments or otherwise.
Footnotes
1 Applies to all Kenvue-owned facilities where Kenvue has operational control, regardless of building type; all leased facilities used for manufacturing and/or research and development; and leased, non-manufacturing and/or non-research and development facilities where the facility is greater than 50,000 square feet and where Kenvue has operational control. The 2020 baseline and all subsequent reporting years include all facilities aligned to Kenvue’s structure upon separation from Johnson & Johnson in 2023 and do not include any operational or organizational exclusions. Scope 1 are greenhouse gas (GHG) emissions that Kenvue directly generates – e.g., running boilers and vehicles using fossil fuels. Fleet emissions are reported as CO2 and do not include other greenhouse gas emissions. Scope 2 are GHG emissions that Kenvue indirectly generates – from electricity or energy purchased for heating and cooling buildings.
2 The inventory was compiled in accordance with the WRI/WBCSD Greenhouse Gas (GHG) Protocol – A Corporate Accounting and Reporting Standard (Revised Edition 2013) including the amendment to this protocol, GHG Protocol Scope 2 Guidance (2015).
3 The target boundary includes land-related emissions and removals from bioenergy feedstocks.
4 Renewable energy source is an energy source that is capable of being replenished in a short time through ecological cycles or agricultural processes (e.g., biomass, geothermal, hydro, solar, wind). Renewable electricity targets are achieved through a combination of actions, including on-site solar, virtual power purchase agreements (VPPAs), direct power purchase agreements (PPAs), energy attribute certificates (EACs), also known as renewable electricity certificates (RECs), and green retail contracts.
5 Survey results represent input gathered from more than 2,300 adults in seven countries from late February to early March 2024.
6 Recyclable, also defined as recycle-ready, is when packaging is designed for collection, sorting, and recycling using end-of-life processes, but where collection, sorting, and recycling infrastructure may not yet be in place for the packaging to actually be recycled. Best practices of “designing for recyclability” guidance for plastic-based packaging include the Association of Plastics Recyclers in the United States. Note: “Designed for recycling,” “designed for recyclability,” and “recycle ready” are also used interchangeably and reflect the same meaning.
7 Kenvue defines refillable packaging as packaging that is designed for either the business or the consumer to put the same type of purchased product back into the original packaging, is designed to be returnable and/or refillable, and accomplishes a minimum number of reuses by being part of a system that enables reuse.
8 Packaging refers to packaging for direct purchases, and may not include all externally manufactured products. Total weight of plastics packaging is calculated utilizing 2024 Business Plan volume and is not trued up to actual sales. Manual adjustments of <10% were made to 2024 Business Plan volume based on subject matter expert judgment to remove materials not assumed to contain plastics.
9 Virgin plastic means newly manufactured resin produced from petrochemical feedstock used as the raw material for the manufacture of plastic products and which has never been used or processed before.
10 Inventory and reporting are aligned with RE100 technical criteria and supplemented by CDP.
11 We aim to meet the goal by end of fiscal year and publish the year after.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240923731043/en/
Contacts
Melissa Witt
media@kenvue.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom